Skip to main content

Table 1 Subject demographic and clinical characteristics (N = 100)

From: A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

Characteristic  
Race,%  
 White 100
Gender,%  
 Male 48
 Female 52
Age at enrollment  
 ≤6 mo,% 52
 <12 mo,% 73
 Mean (SD), mo 8.2 (6.3)
 Median (range), mo 6.0 (<1 − 24.0)
Mean (SD) birth weight, kg 2.14 (1.02)
Mean (SD) gestational age, wk 33.4 (5.1)
Medical history,%  
 Pulmonary* 68
  Respiratory distress syndrome/BPD 52
  Pneumonia 25
  Bronchitis/bronchiolitis 15
  Asthma/reactive airway disease 8
  RSV-related LRTI 1
 Cardiovascular 61
  Murmur 42
    Pathologic 30
    Functional 12
 Congenital heart disease 41
  Acyanotic 28
  Cyanotic 13
 Pulmonary hypertension 10
 Congestive heart failure 7
 Cardiac arrhythmia 1
Hospitalized at birth in intensive/critical care unit,% 67
Hospitalized after birth, prior to study enrollment,% 64
  1. BPD bronchopulmonary dysplasia; LRTI lower respiratory tract infection; RSV respiratory syncytial virus.
  2. *Subjects could contribute to more than 1 category.